Drugs / Peginterferon Lambda
Peginterferon Lambda
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02063607 | Dec 2013 → Feb 2015 | hepatitis C virus infection | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05953545 | May 2024 | hepatitis D virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Withdrawn | No outcome recorded |
| Phase 2 | NCT03600714 | Aug 2018 → Feb 2020 | hepatitis D virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peg-interferon lambda | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03600714 ↗ |
| Known as | Peginterferon Lamda 1 | “Peglamda (Peginterferon Lamda 1)” NCT02063607 ↗ |
| Known as | Peglamda | “Peglamda (Peginterferon Lamda 1)” NCT02063607 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Peginterferon lambda” NCT02063607 ↗ |
| Route | Other | “1 as a weekly injection” NCT03600714 ↗ |